H. Theml
Impact in
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research
- Drug Discovery top 10%
Papers in
- Genetics 15
- Chronic Lymphocytic Leukemia Research 14
-
- Lymphoma Diagnosis and Treatment 14
H. Theml
25 papers receiving 375 citations
Peers
Comparison fields: 5 of 71
- Genetics 177
- Drug Discovery 2
- Immunology 170
- Pathology and Forensic Medicine 139
- Hematology 40
Countries citing papers authored by H. Theml
This map shows the geographic impact of H. Theml's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Theml with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Theml more than expected).
Fields of papers citing papers by H. Theml
This network shows the impact of papers produced by H. Theml. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Theml. The network helps show where H. Theml may publish in the future.
Co-authorship network
The 25 scholars most cited alongside H. Theml, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Color atlas of hematology : practical microscopic and clinical diagnosis | 2004 | 39 |
| 2 | 2004 | 24 | |
| 3 | 1997 | 2 | |
| 4 | 1984 | 11 | |
| 5 | 1983 | 33 | |
| 6 | Treatment of non-hodgkin's lymphoma of low-grade malignancy with human fibroblast interferon. | 1983 | 12 |
| 7 | 1983 | 2 | |
| 8 | 1983 | 27 | |
| 9 | 1982 | 3 | |
| 10 | 1982 | 2 | |
| 11 | 1979 | 63 | |
| 12 | 1977 | 25 | |
| 13 | [Retrospective analysis of the clinical relevance of the Kiel classification of malignant non-Hodgkin's lymphomas (author's transl)]. | 1977 | 18 |
| 14 | 1977 | 10 | |
| 15 | [Clinical observations to characterize splenomegalic immunocytomas (author's transl)]. | 1977 | 5 |
| 16 | 1975 | 16 | |
| 17 | 1973 | 17 | |
| 18 | 1973 | 52 | |
| 19 | [Recirculation of lymphocytes in patients with malignant lymphatic systemic diseases]. | 1972 | 5 |
| 20 | [Nucleic acid synthesis and cytostatic drug effect in pathological lymph node cells]. | 1966 | 10 |
About H. Theml
H. Theml is a scholar working on Genetics, Pathology and Forensic Medicine, Dermatology, Immunology and Oncology, having authored 25 papers that have together received 407 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (14 papers), Glycosylation and Glycoproteins Research (2 papers), Immune Cell Function and Interaction (2 papers), Cutaneous lymphoproliferative disorders research (2 papers), Acute Lymphoblastic Leukemia research (2 papers), Cancer Genomics and Diagnostics (2 papers) and Vascular Tumors and Angiosarcomas (1 paper). The work is most often cited by research in Genetics (177 citations), Drug Discovery (2 citations), Immunology (170 citations), Pathology and Forensic Medicine (139 citations) and Hematology (40 citations). H. Theml has collaborated with scholars based in Germany, Austria and Croatia. Frequent co-authors include Herbert Begemann, F. Trepel, Torsten Haferlach, Heinz Diem, Peter Schick, D. Huhn, Peter G. Dormer, H. Rodt, Theodor M. Fliedner and E. Thiel. Their work appears in journals such as Annals of Hematology, Blood, Journal of Molecular Medicine, Acta Haematologica and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.